News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
With the establishment of five different precious metals alloy powder production methods
RHTC will address a long-standing healthcare access issue for all the local population
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The company is confident of addressing all the observations within the stipulated time
Subscribe To Our Newsletter & Stay Updated
